New collaboration with Dr David Durantel’s team

Published on 30/09/2021

Following the positive proof-of-concept data from 203 study of Vonafexor in combination with pegylated-Interferon (peg-IFN) in viremic patients with chronic hepatitis B (CHB), a new collaboration was initiated with the team of David Durantel at the International Center for Research in Infectiology (CIRI – INSERM U1111, https://ciri.ens-lyon.fr/teams/HepVir).

Read next in 'Latest news'

• The first patient dosed in the Phase 2 ALPESTRIA-1 clinical study of Vonafexor for Alport syndrome
• The Phase 2 ALPESTRIA-1 clinical study has started with Vonafexor on Alport syndrome
• Orphan Drug Designation (ODD) granted to Vonafexor for Alport syndrome by both the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA)
• New publication: Hepatic and renal improvements with FXR agonist Vonafexor in individuals with suspected fibrotic NASH
• New publication : An anti-diabetic drug targets NEET (CISD) proteins through destabilization of their [2Fe-2S] clusters